Pylclari is a diagnostic medicine used in adults with prostate cancer to detect prostate cancer cells with a protein called prostate‑specific membrane antigen (PSMA), using the body scan known as positron-emission tomography (PET). It is used: - to find out whether prostate cancer has spread to lymph nodes and other tissues outside the prostate before treatment is started; - to find out whether prostate cancer has returned in patients whose blood levels of prostate specific antigen (PSA) are increasing after previous treatment. Pylclari contains the active substance piflufolastat (18F).
Therapeutic Indication
### Therapeutic indication This medicinal product is for diagnostic use only. Pylclari is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings: - Primary staging of patients with high-risk PCa prior to initial curative therapy, - To localize recurrence of PCa in patients with a suspected recurrence based on increasing serum prostate-specific antigen (PSA) levels after primary treatment with curative intent. Pylclari is indicated for use with positron emission tomography (PET).
Therapeutic Area (MeSH)
N/AATC Code
V09
ATC Item
诊断用放射性药物
Pharmacotherapeutic Group
Diagnostic radiopharmaceuticals
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| Piflufolastat (18F) | N/A | piflufolastat (18F) |
EMA Name
Pylclari
Medicine Name
Pylclari
Aliases
N/ANo risk management plan link.
